BioSpace News Archive

Precision BioSciences, Inc. today announced completion of a strategic transaction with TG Therapeutics, Inc. (Nasdaq: TGTX) for an exclusive license to develop Azercabtagene Zapreleucel (azer-cel) for autoimmune diseases, and other indications outside of cancer.

ZYUS Life Sciences Corporation today announced that it has strengthened its leadership team with the appointment of Scott Livingstone to the role of Vice President of Clinical Research.

Danaher Corporation and the Innovative Genomics Institute launched a collaborative center to develop gene-editing therapies for rare and other diseases, with a goal of creating a new model for future development of a wide range of genomic medicines.

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced a year end summary of its corporate and product development progress.

Cogent Biosciences, Inc., a biotechnology company focused on developing precision therapies for genetically defined diseases, highlighted the company’s key 2024 milestones ahead of its presentation at J.P. Morgan’s 42nd annual healthcare conference.

Organovo Holdings, Inc. (NASDAQ: ONVO) based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as strong preclinical data, today announced that its data on the activity of FXR314 in its proprietary 3D human tissue models of Crohn’s disease and ulcerative colitis will be presented at the Crohn’s and Colitis Congress to be held January 25-27, 2024 in Las Vegas, Nevada.

Keros Therapeutics, Inc. announced the closing of the previously announced underwritten public offering of 4,025,000 shares of common stock on January 8, 2024, at a public offering price of $40.00 per share, inclusive of the underwriters’ exercise in full of their option to purchase up to an additional 525,000 shares of common stock at the public offering price.

Biosense Webster, Inc. today announced approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for the VARIPULSE™ Platform for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation (AFib) using pulsed field ablation (PFA).

Renibus Therapeutics® today announced publication in E-Clinical Medicine, part of The Lancet Discovery Science, of results from the Phase 2 study evaluating RBT-1, the Company’s first-in-a-new-class preconditioning agent, under investigation to reduce post-operative complications following cardiothoracic surgery.

NOWDiagnostics (NOWDx), a developer of over-the-counter (OTC) and point-of-care (POC) diagnostics tests and first-in-class technology and platforms, today announced they have submitted a De Novo Classification Request to the U.S. Food and Drug Administration (FDA) for the company’s First to Know™ at-home syphilis test.